Periodical
View in EDS

Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination

Bibliographic Details
Title: Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination
Authors: Barouch, Dan H., Santra, Sampa, Kuroda, Marcelo J., Schmitz, Jo¨rn E., Plishka, Ronald, Buckler-White, Alicia, Gaitan, Alicia E., Zin, Rebekah, Nam, Jae-Hwan, Wyatt, Linda S., Lifton, Michelle A., Nickerson, Christine E., Moss, Bernard, Montefiori, David C., Hirsch, Vanessa M., Letvin, Norman L.
Source: The Journal of Virology; June 2001, Vol. 75 Issue: 11 p5151-5158, 8p
Abstract: ABSTRACTSince cytotoxic T lymphocytes (CTLs) are critical for controlling human immunodeficiency virus type 1 (HIV-1) replication in infected individuals, candidate HIV-1 vaccines should elicit virus-specific CTL responses. In this report, we study the immune responses elicited in rhesus monkeys by a recombinant poxvirus vaccine and the degree of protection afforded against a pathogenic simian-human immunodeficiency virus SHIV-89.6P challenge. Immunization with recombinant modified vaccinia virus Ankara (MVA) vectors expressing SIVmac239gag-poland HIV-1 89.6 envelicited potent Gag-specific CTL responses but no detectable SHIV-specific neutralizing antibody (NAb) responses. Following intravenous SHIV-89.6P challenge, sham-vaccinated monkeys developed low-frequency CTL responses, low-titer NAb responses, rapid loss of CD4+T lymphocytes, high-setpoint viral RNA levels, and significant clinical disease progression and death in half of the animals by day 168 postchallenge. In contrast, the recombinant MVA-vaccinated monkeys demonstrated high-frequency secondary CTL responses, high-titer secondary SHIV-89.6-specific NAb responses, rapid emergence of SHIV-89.6P-specific NAb responses, partial preservation of CD4+T lymphocytes, reduced setpoint viral RNA levels, and no evidence of clinical disease or mortality by day 168 postchallenge. There was a statistically significant correlation between levels of vaccine-elicited CTL responses prior to challenge and the control of viremia following challenge. These results demonstrate that immune responses elicited by live recombinant vectors, although unable to provide sterilizing immunity, can control viremia and prevent disease progression following a highly pathogenic AIDS virus challenge.
Database: Supplemental Index
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edo&genre=article&issn=0022538X&ISBN=&volume=75&issue=11&date=20010601&spage=5151&pages=5151-5158&title=The Journal of Virology&atitle=Reduction%20of%20Simian-Human%20Immunodeficiency%20Virus%2089.6P%20Viremia%20in%20Rhesus%20Monkeys%20by%20Recombinant%20Modified%20Vaccinia%20Virus%20Ankara%20Vaccination&aulast=Barouch%2C%20Dan%20H.&id=DOI:10.1128/JVI.75.11.5151-5158.2001
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: edo
DbLabel: Supplemental Index
An: ejs7948027
RelevancyScore: 816
AccessLevel: 6
PubType: Periodical
PubTypeId: serialPeriodical
PreciseRelevancyScore: 816.204528808594
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Barouch%2C+Dan+H%2E%22">Barouch, Dan H.</searchLink><br /><searchLink fieldCode="AR" term="%22Santra%2C+Sampa%22">Santra, Sampa</searchLink><br /><searchLink fieldCode="AR" term="%22Kuroda%2C+Marcelo+J%2E%22">Kuroda, Marcelo J.</searchLink><br /><searchLink fieldCode="AR" term="%22Schmitz%2C+Jo¨rn+E%2E%22">Schmitz, Jo¨rn E.</searchLink><br /><searchLink fieldCode="AR" term="%22Plishka%2C+Ronald%22">Plishka, Ronald</searchLink><br /><searchLink fieldCode="AR" term="%22Buckler-White%2C+Alicia%22">Buckler-White, Alicia</searchLink><br /><searchLink fieldCode="AR" term="%22Gaitan%2C+Alicia+E%2E%22">Gaitan, Alicia E.</searchLink><br /><searchLink fieldCode="AR" term="%22Zin%2C+Rebekah%22">Zin, Rebekah</searchLink><br /><searchLink fieldCode="AR" term="%22Nam%2C+Jae-Hwan%22">Nam, Jae-Hwan</searchLink><br /><searchLink fieldCode="AR" term="%22Wyatt%2C+Linda+S%2E%22">Wyatt, Linda S.</searchLink><br /><searchLink fieldCode="AR" term="%22Lifton%2C+Michelle+A%2E%22">Lifton, Michelle A.</searchLink><br /><searchLink fieldCode="AR" term="%22Nickerson%2C+Christine+E%2E%22">Nickerson, Christine E.</searchLink><br /><searchLink fieldCode="AR" term="%22Moss%2C+Bernard%22">Moss, Bernard</searchLink><br /><searchLink fieldCode="AR" term="%22Montefiori%2C+David+C%2E%22">Montefiori, David C.</searchLink><br /><searchLink fieldCode="AR" term="%22Hirsch%2C+Vanessa+M%2E%22">Hirsch, Vanessa M.</searchLink><br /><searchLink fieldCode="AR" term="%22Letvin%2C+Norman+L%2E%22">Letvin, Norman L.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: The Journal of Virology; June 2001, Vol. 75 Issue: 11 p5151-5158, 8p
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: ABSTRACTSince cytotoxic T lymphocytes (CTLs) are critical for controlling human immunodeficiency virus type 1 (HIV-1) replication in infected individuals, candidate HIV-1 vaccines should elicit virus-specific CTL responses. In this report, we study the immune responses elicited in rhesus monkeys by a recombinant poxvirus vaccine and the degree of protection afforded against a pathogenic simian-human immunodeficiency virus SHIV-89.6P challenge. Immunization with recombinant modified vaccinia virus Ankara (MVA) vectors expressing SIVmac239gag-poland HIV-1 89.6 envelicited potent Gag-specific CTL responses but no detectable SHIV-specific neutralizing antibody (NAb) responses. Following intravenous SHIV-89.6P challenge, sham-vaccinated monkeys developed low-frequency CTL responses, low-titer NAb responses, rapid loss of CD4+T lymphocytes, high-setpoint viral RNA levels, and significant clinical disease progression and death in half of the animals by day 168 postchallenge. In contrast, the recombinant MVA-vaccinated monkeys demonstrated high-frequency secondary CTL responses, high-titer secondary SHIV-89.6-specific NAb responses, rapid emergence of SHIV-89.6P-specific NAb responses, partial preservation of CD4+T lymphocytes, reduced setpoint viral RNA levels, and no evidence of clinical disease or mortality by day 168 postchallenge. There was a statistically significant correlation between levels of vaccine-elicited CTL responses prior to challenge and the control of viremia following challenge. These results demonstrate that immune responses elicited by live recombinant vectors, although unable to provide sterilizing immunity, can control viremia and prevent disease progression following a highly pathogenic AIDS virus challenge.
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edo&AN=ejs7948027
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1128/JVI.75.11.5151-5158.2001
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 5151
    Titles:
      – TitleFull: Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Barouch, Dan H.
      – PersonEntity:
          Name:
            NameFull: Santra, Sampa
      – PersonEntity:
          Name:
            NameFull: Kuroda, Marcelo J.
      – PersonEntity:
          Name:
            NameFull: Schmitz, Jo¨rn E.
      – PersonEntity:
          Name:
            NameFull: Plishka, Ronald
      – PersonEntity:
          Name:
            NameFull: Buckler-White, Alicia
      – PersonEntity:
          Name:
            NameFull: Gaitan, Alicia E.
      – PersonEntity:
          Name:
            NameFull: Zin, Rebekah
      – PersonEntity:
          Name:
            NameFull: Nam, Jae-Hwan
      – PersonEntity:
          Name:
            NameFull: Wyatt, Linda S.
      – PersonEntity:
          Name:
            NameFull: Lifton, Michelle A.
      – PersonEntity:
          Name:
            NameFull: Nickerson, Christine E.
      – PersonEntity:
          Name:
            NameFull: Moss, Bernard
      – PersonEntity:
          Name:
            NameFull: Montefiori, David C.
      – PersonEntity:
          Name:
            NameFull: Hirsch, Vanessa M.
      – PersonEntity:
          Name:
            NameFull: Letvin, Norman L.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: June 2001
              Type: published
              Y: 2001
          Identifiers:
            – Type: issn-print
              Value: 0022538X
            – Type: issn-print
              Value: 10985514
          Numbering:
            – Type: volume
              Value: 75
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: The Journal of Virology
              Type: main
ResultId 1